avalotx.com - AVTX Aggregate Business Value
Avalo Therapeutics, Inc (AVTX) develops treatments for immune pathologies with demand that remains independent of economic conditions. The company's price evolution on GURU.Markets shows an Enterprise Value of -13.55. Management is currently updating its strategy following an asset shift, while the business faces intense patent disputes and high risks of clinical trial failure, which are critical factors for the issuer's attractiveness.
Avalo Therapeutics, Inc (AVTX) - metric breakdowns and financial figures
- stock price and consensus target price:
- issuer market value details:
- issuer book value statistics:
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio Avalo Therapeutics, Inc|AVTX - Long-Term Debt to Capital|Short-Term Debt to Capital avalotx.com|AVTX - Company Debts|Debt to Net Assets Ratio Avalo Therapeutics|AVTX - Company Long-Term Debt|Company Current Liabilities Avalo Therapeutics|Quick Ratio avalotx.com
- earnings and valuation multiples indicators:
Analysis of all company metrics:Avalo Therapeutics, Inc.
For the biotech sector of Avalo Therapeutics, Inc (AVTX), business resilience depends not on market cycles, but on clinical trial results. Analyzing the current enterprise value, an investor sees the real acquisition price of the asset, calculated as the sum of market capitalization and debt minus cash. This metric filters out speculative noise, allowing for an objective assessment of the business value in a full buyout.
Competitors of Avalo Therapeutics, Inc (AVTX)
argenx N.V. - Total Company Value|BNTX: Real Price to Acquire Entire Company|Abivax Pharma - Aggregate Business Value|ADMA (ADMA Biologics) - Real Price to Acquire Entire Company|Business Value PTGX|Total Company Value Immunovant|Kiniksa Pharmaceuticals, Ltd. - Full Business Value|Enterprise Value GRFS|ADPT (Adaptive Biotechnologies Inc.) - Value Adjusted for Debt and Cash|Enterprise Value CLDX (Celldex Therapeutics)|Enterprise Value auriniapharma.com AUPH|BCRX - Total Company Value|Value Adjusted for Debt and Cash VERA (Vera Therapeutics Inc)|Dianthus Pharma (DNTH) - Total Company Value|Real Price to Acquire Entire Company Pharvaris Pharma|ABCL (AbCellera Biologics Inc) - Enterprise Value|Enterprise Value tourmalinebio.com|Real Price to Acquire Entire Company PGEN (Precigen)|PHAR (Pharming Group NV) - Value Adjusted for Debt and Cash|Enterprise Value NKTR (Nektar)|Company Buyout Price Upstream Pharma (UPB)|ZBIO - Total Company Value|immunome.com (IMNM) - Real Price to Acquire Entire Company|Gossamer Bio (GOSS) - Total Company Value|Real Price to Acquire Entire Company KalVista Pharma|Real Price to Acquire Entire Company SEPN|Enterprise Value Pieris Corp|Total Company Value Savara Inc. (SVRA)|rigel.com - Business Value|Enterprise Value ANAB (AnaptysBio)|Astria Therapeutics Inc (ATXS) - Total Enterprise Value|enGene Bio - Enterprise Value|RAPT - Enterprise Value|JBIO (aerovatetx.com) - Real Price to Acquire Entire Company|ACRS (aclaristx.com) - Total Company Value|KYTX (Kyverna Therapeutics, Inc.) - Enterprise Value|Enterprise Value Tiziana Life Sciences Ltd.|Total Company Value Cabaletta Bio, Inc (CABA)|Total Company Value VTYX (Ventyx Biosciences, Inc)|Total Company Value Theratechnologies Inc. THTX|eledon.com (ELDN) - Total Enterprise Value|AGEN: Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash CLYM (Climb Bio Inc.)|ZURA (Zura Bio) - Real Price to Acquire Entire Company|ATYR: Aggregate Business Value|ADAG (Adagene Inc) - Enterprise Value|IMA: Value Adjusted for Debt and Cash|Enterprise Value STTK|EQ - Total Enterprise Value|Total Company Value Connect Biopharma Holdings Limited CNTB|Value Adjusted for Debt and Cash IMUX|Atara Biotherapeutics Inc - Enterprise Value|IFRX - Enterprise Value|X4 Pharmaceuticals, Inc. (XFOR) - Total Company Value|Full Business Value ACET (Adicet Bio, Inc.)|CELU (Celularity Inc) - Enterprise Value|Total Enterprise Value INmune Bio Corporation INMB|Real Price to Acquire Entire Company BRNS (Barinthus Biotherapeutics)|Enterprise Value kezarlifesciences.com (KZR)|SAB Biotherapeutics, Inc. - Real Price to Acquire Entire Company|Aggregate Business Value AKTX (Akari Therapeutics PLC)|Enlivex Therapeutics, Ltd. - Enterprise Value|Company Buyout Price Q32 Bio Inc. QTTB|GOVX: Enterprise Value|Real Price to Acquire Entire Company edesabiotech.com|Total Company Value iBio|Carisma Tx (CARM) - Company Buyout Price|Real Price to Acquire Entire Company XTLB (XTL Biopharmaceuticals, Ltd.)|BOLT (boltbio.com) - Value Adjusted for Debt and Cash|Enterprise Value HCWB (HCW Biologics)|Company Buyout Price Aptevo Therapeutics, Inc. (APVO)|AIM - Total Company Value|ADTX (Aditxt) - Business Value|GRI: Enterprise Value|Real Price to Acquire Entire Company XORTX Corp|HIND (Vyome Holdings Inc) - Enterprise Value|Enterprise Value revbiosciences.com|Real Price to Acquire Entire Company INDP (Indaptus Therapeutics, Inc.)|Total Company Value SCNI (Scinai Immunotherapeutics Ltd)|CalciMedica - Real Price to Acquire Entire Company|Aggregate Business Value AFMD (Affimed NV)|ALLK: Real Price to Acquire Entire Company|HOOK (HOOKIPA Pharma Inc.) - Business Value|igmbio.com (IGMS) - Total Company Value|Full Business Value ITOS (iTeos Therapeutics Inc)|OCEA (Ocean Bio) - Enterprise Value|TCBP: Value Adjusted for Debt and Cash|Enterprise Value THRD